Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies

US7824684B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Yvo Graus · Ede, NL
• Jacques Himber · Guebwiller, FR
• Miranda Jansen-Molenaar · Maarssen, NL
• Dorothee Kling · Kandern, DE
• Erhard Kopetzki · Penzberg, DE
• Paul Parren · Utrecht, NL
• Frank Rebers · Utrecht, NL
• Beat Steiner · Bättwil, CH
• Anne Stern · Penzberg, DE
• Pamela Strein · Schwanau, DE
• Kay-Gunnar Stubenrauch · Frauenfeld, CH
• Jan Van De Winkel · Utrecht, NL
• Martine Van Vugt · Houten, NL

Key dates

• Filing date: Apr 27, 2010
• Grant date: Nov 2, 2010
• Expiry date: Apr 27, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).